| Psoriasis vulgaris
Bryhali vs Hyrimoz
Side-by-side clinical, coverage, and cost comparison for psoriasis vulgaris.Deep comparison between: Bryhali vs Hyrimoz with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsHyrimoz has a higher rate of injection site reactions vs Bryhali based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Hyrimoz but not Bryhali, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Bryhali
Hyrimoz
At A Glance
Topical
Daily
Topical corticosteroid
SC injection
Every other week
TNF-alpha antagonist
Indications
- Psoriasis vulgaris
- Rheumatoid Arthritis
- Juvenile rheumatoid arthritis
- Arthritis, Psoriatic
- Ankylosing spondylitis
- Crohn Disease
- Ulcerative Colitis
- Psoriasis Vulgaris
- Hidradenitis
- Uveitis
Dosing
Psoriasis vulgaris Apply a thin layer to affected areas once daily; do not exceed 8 weeks of treatment or approximately 50 g per week; discontinue when control is achieved; avoid occlusive dressings unless directed, and do not use on face, groin, or axillae.
Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing spondylitis 40 mg SC every other week; some RA patients not receiving MTX may benefit from 40 mg every week or 80 mg every other week.
Juvenile rheumatoid arthritis Weight-based SC dosing every other week for patients >=2 years: 10 mg (10 to <15 kg), 20 mg (15 to <30 kg), or 40 mg (>=30 kg); same dosing applies to pediatric uveitis patients.
Crohn Disease Adults: 160 mg on Day 1, 80 mg on Day 15, then 40 mg SC every other week starting Day 29; pediatric patients >=6 years receive weight-based loading doses followed by 20 or 40 mg every other week.
Ulcerative Colitis Adults: 160 mg on Day 1, 80 mg on Day 15, then 40 mg SC every other week starting Day 29; discontinue if no clinical remission by Day 57.
Psoriasis Vulgaris, Uveitis 80 mg initial SC dose, then 40 mg every other week starting one week after initial dose.
Hidradenitis Adults: 160 mg Day 1, 80 mg Day 15, then 40 mg every week or 80 mg every other week SC starting Day 29; adolescents >=12 years receive weight-based dosing (80 mg Day 1 for 30 to <60 kg, or 160 mg Day 1 for >=60 kg).
Contraindications
—
—
Adverse Reactions
Most common (>=1%) Upper respiratory tract infection, application site dermatitis, hyperglycemia
Most common (>=5%) Injection site reactions, upper respiratory infection, headache, rash, sinusitis, nausea, abdominal pain, back pain, urinary tract infection, flu syndrome, accidental injury, hypertension.
Serious Serious infections (pneumonia, septic arthritis, erysipelas, cellulitis, diverticulitis, pyelonephritis), malignancies, hypersensitivity reactions, hepatitis B reactivation, neurologic reactions, hematological reactions, heart failure, autoimmunity.
Postmarketing Diverticulitis, large bowel perforations, pancreatitis, liver failure, autoimmune hepatitis, sarcoidosis, Merkel Cell Carcinoma, demyelinating disorders, cerebrovascular accident, interstitial lung disease, pulmonary embolism, Stevens Johnson Syndrome, cutaneous vasculitis, erythema multiforme, new or worsening psoriasis, alopecia, systemic vasculitis, deep vein thrombosis.
Pharmacology
Topical corticosteroid; corticosteroids play a role in cellular signaling, immune function, inflammation, and protein regulation, though the precise mechanism of action in plaque psoriasis is unknown.
TNF-alpha antagonist; adalimumab-adaz is a recombinant human IgG1 monoclonal antibody that binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors, also lysing surface TNF-expressing cells in vitro in the presence of complement.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Bryhali
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (6/12) · Qty limit (9/12)
Hyrimoz
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Bryhali
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Hyrimoz
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (6/8) · Qty limit (6/8)
Humana
Bryhali
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (2/3) · Qty limit (2/3)
Hyrimoz
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Bryhali.
No savings programs available for Hyrimoz.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
BryhaliView full Bryhali profile
HyrimozView full Hyrimoz profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.